Retrospective Study
Copyright ©The Author(s) 2021.
World J Transplant. Dec 18, 2021; 11(12): 512-522
Published online Dec 18, 2021. doi: 10.5500/wjt.v11.i12.512
Table 1 Clinical characteristics and tuberculin skin test results of 213 cirrhotic patients who underwent liver transplantation between January 2005 and December 2012, n (%)
Characteristic
General
TST positive
TST negative
P1
(n = 213)
(n = 35)
(n = 178)
Age (yr)53.2 ± 11.056.1 ± 8.652.6 ± 11.30.13
Male153 (71.8)25 (71.4)128 (71.9)0.95
Cirrhosis etiology
Viral hepatitis 68 (31.9)12 (34.3)56 (31.5)
Alcoholic64 (30.0)13 (37.1)51 (28.7)
Cryptogenic 45 (21.1)6 (17.1)39 (21.9)0.01
AIH, PBC, PSC27 (12.7)0 (0)27 (15.2)
Other etiologies9 (4.2)4 (11.4)5 (2.8)
Previous contact with TB patients 18 (8.5)6 (20.0)12 (8.3)0.09
Hepatocellular carcinoma41 (19.2)11 (31.4)30 (16.9)0.046
MELD score16.4 ± 5.015.4 ± 4.016.6 ± 5.10.22
MELD Na18.2 ± 5.316.5 ± 4.518.5 ± 5.40.045
Child
Child A 39 (18.3)11 (31.4)28 (15.7)
Child B 107 (50.2)14 (40.0)93 (52.2)0.136
Child C67 (31.5)10 (28.6)57 (32.0)
Hemoglobin12.2 ± 1.912.6 ± 2.312.1 ± 1.70.257
Creatinine (mg/dL)0.99 ± 0.620.93 ± 0.251.00 ± 0.670.471
Albumin (g/dL)3.1 ± 0.63.3 ± 0.83.1 ± 0.50.181
Sodium (mEq/L)137.7 ± 4.7139.5 ± 4.6137.3 ± 4.70.043
Bilirubin (mg/dL)4.33 ± 5.962.92 ± 1.764.60 ± 6.440.364
INR1.62 ± 0.431.59 ± 0.391.62 ± 0.440.795
Table 2 Usage time of isoniazid and reason for drug withdraw in patients with positive tuberculin skin test
Patient
Usage time (d)
Reason for drug withdraw
Patient 1> 180LTBI treatment complete
Patient 2> 180LTBI treatment complete
Patient 3> 180LTBI treatment complete
Patient 457Changes in liver enzymes
Patient 580Cholestasis
Patient 693Clinical worsening - polyserositis
Patient 7112Not justified
Patient 8142Not justified
Patient 9146Not justified
Patient 10162Not justified
Patient 11171Not justified
Patient 12172Not justified